Back to Results
First PageMeta Content
Melanoma / Vemurafenib / BRAF / PDK1 / Pyruvate dehydrogenase kinase / Mammalian target of rapamycin / Targeted therapy / Biology / Medicine / Chemistry


Opportunity Combination of mutant BRAF inhibitor with Pyruvate Dehydrogenase Kinase isoform 1 (PDK-1) inhibitor for treatment of melanoma/ overcoming BRAF inhibitor resistance •
Add to Reading List

Document Date: 2015-06-08 08:44:48

Open Document

File Size: 257,71 KB

Share Result on Facebook

City

Amsterdam / /

Company

Novartis / /

Country

Netherlands / /

/

Facility

the Netherlands Cancer Institute / /

IndustryTerm

treatment of melanoma / melanoma therapy / cancer therapy / as melanoma therapy / cancer treatment / interleukindependent inflammatory network / /

MedicalCondition

near-complete tumor / BRAF mutant melanoma / highly aggressive cancer / cancer / mutant BRAF-associated human tumors / tumors / Melanoma Background Malignant melanoma / interleukindependent inflammatory network Cell / human melanomas / diabetes / melanoma skin cancers / melanoma / cutaneous melanoma / primary cutaneous melanoma / tumours / /

MedicalTreatment

cancer therapy / /

Organization

FDA / the Netherlands Cancer Institute / /

Person

Van Doorn / Daniel Peeper / Marije Marsman / /

/

Position

Manager NKI/AVL Plesmanlaan / Technology Transfer Manager / /

Technology

treating cancer / drug development / /

URL

http /

SocialTag